Sequana Medical (SEQUA) Stock Overview
Develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
SEQUA Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Sequana Medical NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.61 |
| 52 Week High | €1.62 |
| 52 Week Low | €0.46 |
| Beta | -0.29 |
| 1 Month Change | 0% |
| 3 Month Change | 16.83% |
| 1 Year Change | -38.22% |
| 3 Year Change | -80.16% |
| 5 Year Change | -93.67% |
| Change since IPO | -92.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| SEQUA | BE Medical Equipment | BE Market | |
|---|---|---|---|
| 7D | 0% | 3.3% | 0.7% |
| 1Y | -38.2% | -23.1% | 19.5% |
Return vs Industry: SEQUA underperformed the Belgian Medical Equipment industry which returned -23.6% over the past year.
Return vs Market: SEQUA underperformed the Belgian Market which returned 20% over the past year.
Price Volatility
| SEQUA volatility | |
|---|---|
| SEQUA Average Weekly Movement | 6.3% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in BE Market | 7.8% |
| 10% least volatile stocks in BE Market | 2.6% |
Stable Share Price: SEQUA's share price has been volatile over the past 3 months compared to the Belgian market.
Volatility Over Time: SEQUA's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 48 | Ian Crosbie | www.sequanamedical.com |
Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium.
Sequana Medical NV Fundamentals Summary
| SEQUA fundamental statistics | |
|---|---|
| Market cap | €43.56m |
| Earnings (TTM) | -€51.85m |
| Revenue (TTM) | n/a |
Is SEQUA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SEQUA income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €355.00 |
| Gross Profit | -€355.00 |
| Other Expenses | €51.85m |
| Earnings | -€51.85m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.73 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -103.2% |
How did SEQUA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/09 04:46 |
| End of Day Share Price | 2026/06/09 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sequana Medical NV is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura Roba | Degroof Petercam |
| David Seynnaeve | Degroof Petercam |
| Jacob Mekhael | KBC Securities NV |